Jumping back into Cognitive rehabilitation, which is a therapeutic approach designed to help individuals regain cognitive function and improve their daily functioning after experiencing brain injuries or cognitive decline.

Today they dive more into how it utilizes various techniques and exercises to stimulate neural pathways, and enhance memory, attention, and problem-solving skills, ultimately promoting brain restoration and adaptation to achieve optimal cognitive performance.

John Cavanagh is an accomplished executive in the field of neurology and brain health, known for his expertise in cognitive rehabilitation and brain restoration therapies. He currently serves as an executive at Restore Brain, PLLC, a prominent healthcare organization based in Dallas, Texas.

With a passion for improving the lives of individuals affected by neurological conditions, John has played a pivotal role in developing innovative treatment protocols and expanding the reach of Restore Brain's services.

The Psychedelic Science 2023 spanned one week with events on-site at the Colorado Convention Center and throughout Denver, CO from June 19-23. Classes and Workshops offered an opportunity to dive into the world of psychedelic medicine on Monday and Tuesday. Followed by the conference Tracks offer a curated guide of sessions focused on 11 exciting stages. 

Dr. Matthew W. Johnson, Ph.D., is a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004.

Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule IV upon potential medical approval.

John Cavanagh is an accomplished executive in the field of neurology and brain health, known for his expertise in cognitive rehabilitation and brain restoration therapies. He currently serves as an executive at Restore Brain, PLLC, a prominent healthcare organization based in Dallas, Texas. With a passion for improving the lives of individuals affected by neurological conditions, John has played a pivotal role in developing innovative treatment protocols and expanding the reach of Restore Brain's services.

In addition to his executive role at Restore Brain, John is also a visionary entrepreneur, having founded and established Manage Brain, LLC, a dynamic company based in Dallas, Texas. Manage Brain is dedicated to providing cutting-edge technologies and solutions for optimizing brain function, cognitive performance, and mental well-being. Under John's leadership, Manage Brain has emerged as a leading provider of neurofeedback systems and brain training programs that help individuals enhance their cognitive abilities and overcome neurological challenges.

The future of neuromodulatory treatments & psychedelic-assisted therapies holds immense promise in revolutionizing mental health treatment. Through rigorous research and growing acceptance, treatments like TMS, Ketamine, psilocybin, MDMA, and LSD are being recognized for their potential to alleviate conditions such as depression, anxiety, PTSD, and addiction. 

As clinical trials continue to demonstrate their safety and efficacy, we can anticipate a broader integration of these therapies into mainstream healthcare, accompanied by regulations to ensure responsible use and trained practitioners. With ongoing advancements and a shift in societal attitudes, psychedelic-assisted therapies have the potential to offer transformative healing experiences and pave the way for a new era of mental well-being.

Tracking data can play a crucial role in enhancing the medical support provided during psychedelic treatments. By closely monitoring patients' experiences, physiological responses, and mental well-being throughout the treatment process, healthcare professionals can gain valuable insights into the efficacy and safety of psychedelic therapies.

Analyzing this data can help identify patterns, personalize treatment plans, and optimize dosage protocols, ultimately leading to more targeted and effective therapeutic outcomes. Additionally, tracking data enables the identification of potential adverse effects, allowing for timely interventions and adjustments to ensure patients receive the best possible care during their psychedelic-assisted therapy.

Beyond Psychedelics is a podcast that explores the therapeutic potential of psychedelics and neuromodulation. The FDA is conducting clinical trials to determine safe dosages for patients and ketamine and MDMA are being used to create a distorted sense of self, leading to a disassociation from the current state of mind to a different state of mind. However, at-home ketamine usage is not regulated or supervised, leading to adverse effects or bad trips. Ketamine-assisted psychotherapy, along with therapy, results in higher efficacy for patients. 

Ketamine blocks NMDA receptors, involved in the transmission of pain signals and mood regulation, leading to an increase in the most abundant neurotransmitter in the brain, glutamate, and a dreamlike state that alters the perception of time and space. The podcast emphasizes the importance of ongoing support for patients after treatment, as well as the need to treat the root cause of mental health issues, not just the symptoms. Mental health professionals need to incorporate other elements of mental health treatment, including counseling and EMDR, along with psychedelic treatments.